| pubmed-article:20828860 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C1122962 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:20828860 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20828860 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20828860 | pubmed:dateCreated | 2011-4-12 | lld:pubmed |
| pubmed-article:20828860 | pubmed:abstractText | A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250 mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III. | lld:pubmed |
| pubmed-article:20828860 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20828860 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20828860 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20828860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20828860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20828860 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20828860 | pubmed:month | May | lld:pubmed |
| pubmed-article:20828860 | pubmed:issn | 1872-8332 | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:FukuokaMasahi... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:NakagawaKazuh... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:OkamotoHiroak... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:WatanabeKoshi... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:OkamotoIsamuI | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:TakahashiTosh... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:NishimuraYasu... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:NakamatsuKiyo... | lld:pubmed |
| pubmed-article:20828860 | pubmed:author | pubmed-author:YamamotoNobuy... | lld:pubmed |
| pubmed-article:20828860 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20828860 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20828860 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:20828860 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20828860 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20828860 | pubmed:pagination | 199-204 | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:meshHeading | pubmed-meshheading:20828860... | lld:pubmed |
| pubmed-article:20828860 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20828860 | pubmed:articleTitle | Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. | lld:pubmed |
| pubmed-article:20828860 | pubmed:affiliation | Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan. chi-okamoto@dotd.med.kindai.ac.jp | lld:pubmed |
| pubmed-article:20828860 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20828860 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1956 | entrezgene:pubmed | pubmed-article:20828860 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20828860 | lld:entrezgene |
